Novartis AG
NVS | NYSE
$141.38
+$0.40 (+0.28%)
Sep 22, 2026, 11:48 AM ET · Market open
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Vasant Narasimhan | Chief Executive Officer |
| Mukul Mehta | Chief Financial Officer |
| Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research |
| Karen L. Hale | Chief Legal & Compliance Officer |
| Patrick Horber | President of International |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Robert Kowalski | Chief People & Organization Officer |
| Sloan Simpson | Global Head of Investor Relations |
| Steffen Lang | President of Operations |
| Victor Bulto | President of US |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 6-K | Filing |
| Sep 01, 2026 | 6-K | Filing |
| Jul 21, 2026 | 6-K | Filing |
| Jun 11, 2026 | 6-K | Filing |
| Apr 28, 2026 | 6-K | Filing |
| Mar 18, 2026 | 6-K | Filing |
| Mar 17, 2026 | 424B5 | Filing |
| Mar 17, 2026 | FWP | Filing |
| Mar 16, 2026 | 424B5 | Filing |
| Feb 04, 2026 | S-8 | Filing |
Novartis AG
| Country | Switzerland |
| IPO Date | Nov 6, 1996 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,267 |
| CEO | Vasant Narasimhan |
Stock Details
| Ticker Symbol | NVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001114448 |
| CUSIP Number | 66987V109 |
| ISIN Number | US66987V1098 |
| SIC Code | 2834 |
Recent News
- 1 day ago / zacks.comNVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
- 6 days ago / reuters.comNovartis halts ALS drug development after mid-stage trial failure
- 7 days ago / reuters.comLegend Biotech taps Novartis veteran Zhang as CEO
- 7 days ago / wsj.comLegend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
- 8 days ago / fool.comNovartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
- 11 days ago / barrons.comNovartis: More Pain on the Way?
- 11 days ago / gurufocus.comNovartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
- 12 days ago / reuters.comFocus: Novartis investors turn spotlight on M&A after trial setbacks
- 12 days ago / reuters.comMajor Novartis shareholder calls for board shake-up after drug trial setbacks
- 13 days ago / zacks.comNovartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Add to Watchlist
Select watchlists to add or remove NVS